Overview

On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection

Status:
Completed
Trial end date:
2011-01-01
Target enrollment:
0
Participant gender:
All
Summary
In this prospective, open, controlled, cross-sectional observational study patients with psoriasis or IBD, who received either anti-TNF-alpha inhibitors or alternates (purine-, folic acid analogues, phototherapy, fumaric ester, mesalazine) for their underlying disease were included. Anogenital HPV-induced lesions, mucosal HPV DNA and serological status of mucosal low-risk (HPV6) and high-risk HPV (HPV16, HPV18) were determined.
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
6-Mercaptopurine
Adalimumab
Etanercept
Folic Acid
Folic Acid Antagonists
Infliximab
Mercaptopurine
Mesalamine
Methotrexate
Sulfasalazine
Vitamin B Complex
Criteria
Inclusion Criteria:

- Participants between 18-80 years of age with a history of psoriasis or inflammatory
bowel diseases, namely Crohn's disease and ulcerative colitis, and

- at least 6 month of continuous treatment regimen.

Exclusion Criteria:

- Pregnant or nursing patients and

- patients with inherited immune disorders, human immunodeficiency virus infection,
invasive malignancies or psychomotor retardation and

- patients with psoriasis or inflammatory bowel diseases who had received high-dose
corticosteroids during the past 6 months.